NLRP3 and Balkan nephropathy: Particularly, to further verify IL-22 as a novel therapeutic agent against AAN by targeting NLRP3 inflammasome activation, more efforts should be devoted to exploring the possible crosstalk between the IL-22 pathway and the NLRP3 inflammasome signaling in order to decipher exactly how IL-22 regulates NLRP3 inflammasome activation.